Thermo Fisher receives FDA approval for NGS-based companion diagnostic for new NSCLC treatment
Oncomine Dx Target Test approved to identify patients eligible for HERNEXEOS (zongertinib tablets), the first and only orally administered targeted treatment for HER2 (ERBB2)-mutant NSCLC